Optimal Strategies for Managing Adverse Events with GPRC5D Bispecifics in Multiple Myeloma : Episode 8
Clinical Experience in Managing AEs in GPRC5D Therapy
Mary Steinbach, APRN, shares her experience in managing dysgeusia and nail- and skin-related toxicities seen in patients with multiple myeloma who receive talquetamab.
Video Player is loading.
EP: 1.Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
EP: 2.Adverse Event Management with BCMA Therapy
EP: 3.GPRC5D Therapy: Unique Challenges in Adverse Event Management
EP: 4.Overview of Long-term Follow-up from MonumenTAL-1
EP: 5.Overview of Other GPRC5D Therapy Clinical Trials
EP: 6.Administration and Dosing Management
EP: 7.Clinical Perspective on AE Tolerance
Now Viewing
EP: 8.Clinical Experience in Managing AEs in GPRC5D Therapy
EP: 9.Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
EP: 10.Insights on REMS Programs and Strategies for Effective Patient Care
EP: 11.Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy
EP: 12.Adverse Event Management Strategies in GPRC5D Therapy
EP: 13.Clinical Scenario: AE Management for Bispecific Therapy in R/R MM
Recent Videos
MRD Recurrence Shown to Precede Biochemical Relapse in Multiple Myeloma
JNJ-5322 Improves Efficacy, Oral Toxicity in Multiple Myeloma
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
Real World Experience of CAR-T in MM Patients
Importance of Multidisciplinary Approach in Care of CAR-T MM Patients
Overview of the Efficacy of Cilta-cel in the CARTITUDE Trials
Future Perspectives: What’s Next in NDMM?
Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
Jackson’s Journey with High Risk R/R MM
Role of Bridging Therapy for CAR-T Patients
Related Content
